APGE - NASDAQ

Apogee Therapeutics, Inc.

APGE·NASDAQ

$84.19

+3.0%

HealthcareBiotechnology

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$5.21B

EPS-4.2200

P/E Ratio-19.95

Earnings Date08/10/2026

apge

Cash and Short Term Investments

Last Annual Value

730.19M

3-Year CAGR

69%

5-Year CAGR

37%

10-Year CAGR

17%

Adjust for Inflation

Apogee Therapeutics, Inc. Competitors Analysis of Cash and Short Term Investments

APGE · NASDAQ

Company	Cash and Short Term Investments	CAGR 3Y	CAGR 5Y	CAGR 10Y
Apogee Therapeutics, Inc. NASDAQ:APGE	730.19M	22.7%	N/A	N/A
Legend Biotech Corporation NASDAQ:LEGN	948.60M	-10.2%	1.5%	N/A
Ultragenyx Pharmaceutical Inc. NASDAQ:RARE	693.00M	6.3%	-1.3%	3.4%
CG Oncology, Inc. Common stock NASDAQ:CGON	742.15M	58.1%	69.1%	N/A
Celcuity Inc. NASDAQ:CELC	441.50M	34.7%	39.3%	54.1%
Disc Medicine, Inc. NASDAQ:IRON	791.15M	30.0%	55.1%	N/A
Soleno Therapeutics, Inc. NASDAQ:SLNO	305.47M	21.7%	70.3%	60.3%

Apogee Therapeutics, Inc. Fair Value Envelope

APGE · NASDAQ

Our analysis suggests that APGE has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $84.19, this represents a potential HIDDEN relative to our calculated worth for Apogee Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $84.19

Related Guides

Blog Categories

Continue your APGE research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.